CANTERBURY HAEMOSTASIS AND THROMBOSIS LTD

Company Registration Number:
12279449 (England and Wales)

Unaudited abridged accounts for the year ended 31 October 2024

Period of accounts

Start date: 01 November 2023

End date: 31 October 2024

CANTERBURY HAEMOSTASIS AND THROMBOSIS LTD

Contents of the Financial Statements

for the Period Ended 31 October 2024

Balance sheet
Notes

CANTERBURY HAEMOSTASIS AND THROMBOSIS LTD

Balance sheet

As at 31 October 2024


Notes

2024

2023


£

£
Called up share capital not paid: 0 0
Fixed assets
Tangible assets: 3 19,485 25,797
Total fixed assets: 19,485 25,797
Current assets
Cash at bank and in hand: 27,670 16,985
Total current assets: 27,670 16,985
Creditors: amounts falling due within one year: 4 (4,525) (4,052)
Net current assets (liabilities): 23,145 12,933
Total assets less current liabilities: 42,630 38,730
Provision for liabilities: (3,702) (4,901)
Total net assets (liabilities): 38,928 33,829
Capital and reserves
Called up share capital: 2 2
Profit and loss account: 38,926 33,827
Shareholders funds: 38,928 33,829

The notes form part of these financial statements

CANTERBURY HAEMOSTASIS AND THROMBOSIS LTD

Balance sheet statements

For the year ending 31 October 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 28 July 2025
and signed on behalf of the board by:

Name: David Stephensen
Status: Director

The notes form part of these financial statements

CANTERBURY HAEMOSTASIS AND THROMBOSIS LTD

Notes to the Financial Statements

for the Period Ended 31 October 2024

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

CANTERBURY HAEMOSTASIS AND THROMBOSIS LTD

Notes to the Financial Statements

for the Period Ended 31 October 2024

2. Employees

2024 2023
Average number of employees during the period 0 0

CANTERBURY HAEMOSTASIS AND THROMBOSIS LTD

Notes to the Financial Statements

for the Period Ended 31 October 2024

3. Tangible Assets

Total
Cost £
At 01 November 2023 36,738
Additions 679
At 31 October 2024 37,417
Depreciation
At 01 November 2023 10,941
Charge for year 6,991
At 31 October 2024 17,932
Net book value
At 31 October 2024 19,485
At 31 October 2023 25,797

CANTERBURY HAEMOSTASIS AND THROMBOSIS LTD

Notes to the Financial Statements

for the Period Ended 31 October 2024

4. Creditors: amounts falling due within one year note

Corporation tax 1,781 Accruals and deferred income 1,175 Directors' loan accounts 1,569 Total 4,525